Neutralizing antibodies (nABs) from patient donors who were infected with SARS-CoV-2, were used on two epitopes: the receptor binding domain (RBD) and non-receptor binding domain on the spike protein to test protection using an animal model. The neutralizing antibodies were tested on a Syrian hamster model at five different concentrations to evaluate dose-response. The hamsters were inoculated with SARS-CoV-2. Hamsters were weighed as a measure of disease and lung tissue was collected to measure viral load. Results suggest that the animals who received 2mg (average of 16.5 mg/kg) or 500 μg (average of 4.2 mg/kg) of neutralizing RBD-A antibody, presented with no weight loss and low viral loads whereas the controls lost an average of 13.6% of their body weight, those that received low doses of AB (0.9, 0.2, 0.06 mg/kg also lost significant body weight. The data suggest that an antibody serum concentration required for protection against SARSCoV-2 in this model was found to be 22 μg/ml of nAb which has full protection and a serum concentration of 12 μg/ml of nAb results in a 50% reduced disease that was measured via weight loss. The RBD-A epitope nABs that compete with Angiotensin-Con-verting Enzyme2 are better for prophylactic and therapeutic applications and may help find neutralizing epitopes to guide future vaccine design.